IMRT for Head and Neck Cancer: Updated Clinical Results

S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: October 22, 2003

Moderator: Theodore L. Phillips, MD., University of California, San Francisco

Nancy Lee, MD, Memorial Sloan-Kettering Cancer Center, New York

  • Approximately 150 papers have reported on the outcomes of H&N cancer patients treated with IMRT.
  • The primary endpoints for these trials usually are rates of xerostomia and local control.
  • It is important to keep in mind that GTV delineation is a multidisciplinary approach requiring the input of the radiation oncologist, neuroradiologist, and the H&N surgeon.
  • CTV delineation requires knowledge of H&N anatomy and patterns of spread.
  • In terms of xerostomia, mean parotid doses of < 26 Gy has resulted in objective and subjective salivary function preservation and improved quality of life.
  • IMRT has resulted in 82% improvement in xerostomia at 12 months compared to 40% improvement with 3DCRT.
  • In terms of local control (LC) in nasopharyngeal cancer, comparison to historical controls have shown the following:
  • For T1-2 lesions, IMRT 92-100% vs. 3DCRT 64-95%
  • For T3-4 lesions, IMRT 92-94% vs. 44-68%
  • For oropharyngeal CA, comparison to historical controls for LC have shown:
  • For T1-2 lesions, IMRT 92% vs. 3DCRT 70-90%
  • For T3-4 lesions, IMRT 87-94% vs. 3DCRT 30-70%
  • Similar high rates of LC are seen for other H&N sites.
  • In conclusion, IMRT has been shown to decrease xerostomia rates and possibly increase local control compared to historical controls, particularly in patients with more advanced disease.
  • These patients may experience higher acute toxicity and likely have an increased risk of second malignancy (from 1% to 1.75%) due to the higher integral dose delivered with IMRT.
  • Although randomized trials would be beneficial, it would be difficult to enroll patients into these studies given the existing, non-randomized data.
  • Two ongoing European trials are currently examining these questions, and the results are eagerly anticipated.

Blogs

Cancer Free(dom)
by Karen Arnold-Korzeniowski, BSN, RN
September 23, 2016

Patient Portals: Finding Their Full Potential
by Patrick Higgins
January 28, 2014

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Stay informed with the latest information from OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives